Calton & Associates’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Calton & Associates’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-790	Closed	-$81K	–	1505
2017 Q4	$81K	Buy	+790	New	+$43.2K	0.02%	538

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Calton & Associates's BIVV Position: Q1 2018 in Review

Calton & Associates sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 790 shares — an estimated $81K sold.

Calton & Associates first reported a position in BIVV in Q4 2017 and held it in 1 quarter. The position peaked at $81K in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Calton & Associates reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 790 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $81K.
Calton & Associates first reported a position in Bioverativ Inc. Common Stock in Q4 2017 and held it in 1 quarter.
Calton & Associates's Bioverativ Inc. Common Stock position peaked at $81K in Q4 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.